Clinical efficacy and safety of Ginsenoside Rg3 combined with Osimertinib in treatment of the first-generation EGFR-TKI-resistant advanced non-small cell lung cancer

Jiang Guanming; Tan Qinquan; Liu Chun; Yao Mantian; Zeng Yihong; Yuan Haiji; Lin Shunhuan

doi:10.3969/j.issn.0253-9802.2019.07.006

Guanming Jiang,Qinquan Tan,Chun Liu,Mantian Yao,Yihong Zeng,Haiji Yuan,Shunhuan Lin

JOURNAL OF NEW MEDICINE ›› 2019, Vol. 50 ›› Issue (7) : 505-509.

PDF(992 KB)

JOURNAL OF NEW MEDICINE ›› 2019, Vol. 50 ›› Issue (7) : 505-509. DOI: 10.3969/j.issn.0253-9802.2019.07.006

Original Research

Clinical efficacy and safety of Ginsenoside Rg3 combined with Osimertinib in treatment of the first-generation EGFR-TKI-resistant advanced non-small cell lung cancer

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

Abstract

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2019, 50(7): 505-509 https://doi.org/10.3969/j.issn.0253-9802.2019.07.006

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

Funding

RIGHTS & PERMISSIONS

PDF(992 KB)

Accesses

Citation

Detail

Sections

Recommended

Received	Published
2019-03-11	2019-07-15
Issue Date
2019-07-25

Please choose a citation manager

Content to export